Michel Chonchol
Concepts (681)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 80 | 2023 | 488 | 11.110 |
Why?
| Polycystic Kidney, Autosomal Dominant | 29 | 2023 | 209 | 8.650 |
Why?
| Kidney Failure, Chronic | 55 | 2023 | 490 | 7.620 |
Why?
| Glomerular Filtration Rate | 86 | 2023 | 605 | 6.410 |
Why?
| Renal Dialysis | 33 | 2023 | 369 | 5.820 |
Why?
| Kidney | 45 | 2023 | 1207 | 5.370 |
Why?
| Fibroblast Growth Factors | 25 | 2020 | 162 | 5.300 |
Why?
| Cardiovascular Diseases | 57 | 2023 | 1724 | 4.870 |
Why?
| Kidney Diseases | 31 | 2023 | 354 | 4.640 |
Why?
| Vitamin D | 31 | 2022 | 341 | 4.230 |
Why?
| Hypertension | 37 | 2022 | 1064 | 3.190 |
Why?
| Vitamin D Deficiency | 12 | 2018 | 159 | 2.670 |
Why?
| Endothelium, Vascular | 17 | 2021 | 845 | 2.460 |
Why?
| Vascular Stiffness | 17 | 2023 | 411 | 2.460 |
Why?
| Blood Pressure | 35 | 2023 | 1537 | 2.440 |
Why?
| Aged | 168 | 2023 | 19251 | 2.240 |
Why?
| Phosphorus | 13 | 2017 | 81 | 2.180 |
Why?
| Nephrology | 5 | 2022 | 48 | 1.990 |
Why?
| Uric Acid | 12 | 2021 | 150 | 1.990 |
Why?
| Middle Aged | 158 | 2023 | 26999 | 1.980 |
Why?
| Male | 220 | 2023 | 55949 | 1.950 |
Why?
| Female | 220 | 2023 | 59913 | 1.880 |
Why?
| Creatinine | 25 | 2021 | 430 | 1.870 |
Why?
| Humans | 291 | 2023 | 115587 | 1.840 |
Why?
| Disease Progression | 40 | 2023 | 2418 | 1.750 |
Why?
| Risk Factors | 87 | 2022 | 8697 | 1.690 |
Why?
| Phosphates | 11 | 2021 | 160 | 1.670 |
Why?
| Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 11 | 1.650 |
Why?
| Cholecalciferol | 5 | 2022 | 47 | 1.640 |
Why?
| Parathyroid Hormone | 18 | 2020 | 95 | 1.620 |
Why?
| Double-Blind Method | 30 | 2023 | 1660 | 1.540 |
Why?
| Dietary Supplements | 10 | 2021 | 458 | 1.520 |
Why?
| Vascular Calcification | 8 | 2022 | 107 | 1.510 |
Why?
| Calcium | 13 | 2020 | 1103 | 1.310 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 373 | 1.290 |
Why?
| Nutrition Surveys | 13 | 2015 | 225 | 1.280 |
Why?
| Kidney Calculi | 3 | 2013 | 30 | 1.280 |
Why?
| Antihypertensive Agents | 14 | 2021 | 432 | 1.270 |
Why?
| Biomarkers | 41 | 2022 | 3466 | 1.260 |
Why?
| Fatty Liver | 10 | 2013 | 217 | 1.250 |
Why?
| Oxidative Stress | 16 | 2023 | 1093 | 1.220 |
Why?
| Inflammation | 19 | 2022 | 2499 | 1.200 |
Why?
| Brachial Artery | 11 | 2018 | 173 | 1.200 |
Why?
| Blood Vessels | 3 | 2019 | 181 | 1.170 |
Why?
| Coronary Disease | 7 | 2010 | 348 | 1.170 |
Why?
| Adult | 74 | 2023 | 30718 | 1.160 |
Why?
| Naphthalenes | 4 | 2015 | 39 | 1.160 |
Why?
| Bacterial Infections | 3 | 2016 | 222 | 1.150 |
Why?
| Coronary Artery Disease | 11 | 2022 | 607 | 1.080 |
Why?
| Prospective Studies | 41 | 2023 | 6264 | 1.070 |
Why?
| Adrenergic beta-Antagonists | 7 | 2011 | 293 | 1.060 |
Why?
| Vascular Diseases | 7 | 2021 | 230 | 1.060 |
Why?
| Pulse Wave Analysis | 10 | 2023 | 207 | 1.040 |
Why?
| Cognition | 6 | 2023 | 980 | 1.030 |
Why?
| Cross-Sectional Studies | 37 | 2022 | 4435 | 1.020 |
Why?
| Acute Kidney Injury | 10 | 2022 | 646 | 1.020 |
Why?
| Hyperparathyroidism, Secondary | 4 | 2009 | 9 | 0.990 |
Why?
| Prevalence | 25 | 2018 | 2264 | 0.980 |
Why?
| Minerals | 6 | 2022 | 37 | 0.950 |
Why?
| Curcumin | 2 | 2021 | 29 | 0.910 |
Why?
| Cognitive Dysfunction | 2 | 2018 | 279 | 0.900 |
Why?
| Aged, 80 and over | 43 | 2023 | 6417 | 0.900 |
Why?
| Pregnancy Complications | 3 | 2018 | 430 | 0.890 |
Why?
| Follow-Up Studies | 37 | 2020 | 4440 | 0.880 |
Why?
| Anemia | 5 | 2020 | 144 | 0.870 |
Why?
| Proportional Hazards Models | 30 | 2019 | 1087 | 0.860 |
Why?
| Incidence | 28 | 2021 | 2335 | 0.850 |
Why?
| Cohort Studies | 31 | 2021 | 4944 | 0.850 |
Why?
| Albuminuria | 13 | 2022 | 164 | 0.840 |
Why?
| Atherosclerosis | 8 | 2021 | 341 | 0.810 |
Why?
| Vascular Surgical Procedures | 13 | 2011 | 262 | 0.810 |
Why?
| Sodium, Dietary | 3 | 2018 | 36 | 0.810 |
Why?
| Non-alcoholic Fatty Liver Disease | 9 | 2016 | 246 | 0.790 |
Why?
| Kidney Transplantation | 3 | 2022 | 558 | 0.760 |
Why?
| Renal Insufficiency | 6 | 2023 | 137 | 0.760 |
Why?
| Kidney Function Tests | 12 | 2017 | 141 | 0.750 |
Why?
| Vitamins | 3 | 2022 | 151 | 0.750 |
Why?
| Vasodilation | 6 | 2018 | 412 | 0.750 |
Why?
| Calcimimetic Agents | 1 | 2020 | 2 | 0.740 |
Why?
| Hyponatremia | 2 | 2018 | 37 | 0.740 |
Why?
| Sodium | 2 | 2019 | 183 | 0.730 |
Why?
| Time Factors | 30 | 2022 | 6165 | 0.720 |
Why?
| Potassium, Dietary | 2 | 2018 | 10 | 0.720 |
Why?
| Cystatin C | 7 | 2013 | 61 | 0.720 |
Why?
| Calcitriol | 2 | 2018 | 53 | 0.720 |
Why?
| Prognosis | 27 | 2021 | 3339 | 0.710 |
Why?
| Bicarbonates | 5 | 2023 | 42 | 0.710 |
Why?
| Systole | 8 | 2020 | 169 | 0.710 |
Why?
| Renin-Angiotensin System | 3 | 2017 | 72 | 0.700 |
Why?
| Renal Artery Obstruction | 3 | 2014 | 30 | 0.700 |
Why?
| Bone Diseases | 1 | 2020 | 58 | 0.690 |
Why?
| Overweight | 2 | 2021 | 469 | 0.690 |
Why?
| Sodium Bicarbonate | 2 | 2023 | 40 | 0.680 |
Why?
| Treatment Outcome | 38 | 2021 | 9159 | 0.670 |
Why?
| Cause of Death | 6 | 2018 | 368 | 0.650 |
Why?
| Interleukin-1 | 3 | 2019 | 971 | 0.650 |
Why?
| Chronic Disease | 19 | 2017 | 1598 | 0.650 |
Why?
| Spironolactone | 1 | 2019 | 33 | 0.650 |
Why?
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 43 | 0.640 |
Why?
| Odds Ratio | 12 | 2017 | 962 | 0.640 |
Why?
| Accidental Falls | 1 | 2020 | 151 | 0.630 |
Why?
| Endothelial Cells | 5 | 2023 | 695 | 0.630 |
Why?
| Hemoglobins | 4 | 2009 | 312 | 0.630 |
Why?
| Acidosis | 2 | 2018 | 87 | 0.620 |
Why?
| Simvastatin | 3 | 2014 | 59 | 0.620 |
Why?
| Hypertrophy, Left Ventricular | 4 | 2017 | 103 | 0.620 |
Why?
| Obesity | 4 | 2021 | 2517 | 0.620 |
Why?
| Heart Diseases | 4 | 2015 | 330 | 0.620 |
Why?
| Frailty | 1 | 2020 | 116 | 0.610 |
Why?
| Interleukin-6 | 3 | 2020 | 677 | 0.610 |
Why?
| Calcium, Dietary | 2 | 2009 | 55 | 0.610 |
Why?
| Death, Sudden, Cardiac | 5 | 2015 | 160 | 0.610 |
Why?
| Arterial Pressure | 1 | 2018 | 95 | 0.610 |
Why?
| Metformin | 1 | 2021 | 278 | 0.600 |
Why?
| United States | 33 | 2020 | 12295 | 0.600 |
Why?
| Recombinant Fusion Proteins | 2 | 2017 | 616 | 0.600 |
Why?
| Longitudinal Studies | 17 | 2020 | 2416 | 0.590 |
Why?
| Carotid Artery Diseases | 3 | 2021 | 58 | 0.580 |
Why?
| Multivariate Analysis | 14 | 2017 | 1440 | 0.570 |
Why?
| Pregnancy Outcome | 3 | 2018 | 336 | 0.570 |
Why?
| Bone Density | 5 | 2017 | 432 | 0.570 |
Why?
| Young Adult | 20 | 2023 | 10470 | 0.560 |
Why?
| Calcinosis | 6 | 2017 | 242 | 0.560 |
Why?
| Conservative Treatment | 1 | 2017 | 29 | 0.550 |
Why?
| Calciphylaxis | 1 | 2016 | 2 | 0.550 |
Why?
| Diabetic Nephropathies | 5 | 2013 | 234 | 0.540 |
Why?
| Uremia | 1 | 2016 | 14 | 0.540 |
Why?
| Logistic Models | 11 | 2017 | 1856 | 0.540 |
Why?
| Kidney Tubules | 4 | 2022 | 107 | 0.530 |
Why?
| Sodium Chloride | 1 | 2017 | 136 | 0.530 |
Why?
| Primary Prevention | 3 | 2018 | 171 | 0.530 |
Why?
| Diabetes Mellitus, Type 2 | 10 | 2012 | 2098 | 0.530 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 180 | 0.530 |
Why?
| Fluid Therapy | 1 | 2017 | 122 | 0.520 |
Why?
| Myocardial Infarction | 10 | 2017 | 931 | 0.520 |
Why?
| Hyperuricemia | 5 | 2018 | 43 | 0.520 |
Why?
| Liver | 2 | 2016 | 1690 | 0.510 |
Why?
| Diet, Sodium-Restricted | 4 | 2020 | 32 | 0.510 |
Why?
| Peripheral Arterial Disease | 7 | 2021 | 379 | 0.510 |
Why?
| Comorbidity | 13 | 2018 | 1473 | 0.500 |
Why?
| Peripheral Vascular Diseases | 7 | 2012 | 98 | 0.500 |
Why?
| Undocumented Immigrants | 3 | 2023 | 41 | 0.500 |
Why?
| Ventricular Dysfunction, Left | 6 | 2014 | 366 | 0.490 |
Why?
| Diabetes Complications | 6 | 2018 | 212 | 0.490 |
Why?
| Survival Rate | 14 | 2020 | 1650 | 0.490 |
Why?
| Risk Assessment | 24 | 2021 | 2987 | 0.480 |
Why?
| Pyrazoles | 2 | 2014 | 362 | 0.480 |
Why?
| Fructose | 2 | 2016 | 100 | 0.480 |
Why?
| Cardiovascular Agents | 4 | 2013 | 125 | 0.470 |
Why?
| Retrospective Studies | 32 | 2020 | 12608 | 0.470 |
Why?
| Pyridines | 2 | 2014 | 425 | 0.470 |
Why?
| Hyperphosphatemia | 4 | 2020 | 13 | 0.450 |
Why?
| Ankle Brachial Index | 4 | 2014 | 30 | 0.440 |
Why?
| Sodium Nitrite | 3 | 2021 | 37 | 0.440 |
Why?
| C-Reactive Protein | 8 | 2018 | 364 | 0.440 |
Why?
| Pneumonia, Bacterial | 1 | 2014 | 108 | 0.430 |
Why?
| TRPP Cation Channels | 5 | 2022 | 63 | 0.430 |
Why?
| Community-Acquired Infections | 1 | 2014 | 140 | 0.420 |
Why?
| Nephrolithiasis | 1 | 2012 | 10 | 0.420 |
Why?
| Randomized Controlled Trials as Topic | 11 | 2021 | 1216 | 0.410 |
Why?
| Lanthanum | 3 | 2021 | 8 | 0.410 |
Why?
| Hemostasis | 2 | 2009 | 67 | 0.410 |
Why?
| Radius | 1 | 2012 | 33 | 0.410 |
Why?
| Magnesium | 2 | 2014 | 145 | 0.400 |
Why?
| Caloric Restriction | 3 | 2023 | 90 | 0.400 |
Why?
| Chi-Square Distribution | 10 | 2017 | 499 | 0.400 |
Why?
| Metabolic Syndrome | 6 | 2014 | 324 | 0.400 |
Why?
| Carotid Arteries | 4 | 2018 | 183 | 0.400 |
Why?
| Internship and Residency | 2 | 2020 | 951 | 0.390 |
Why?
| Coronary Artery Bypass | 3 | 2014 | 196 | 0.390 |
Why?
| Health Status | 3 | 2015 | 728 | 0.390 |
Why?
| Resistance Training | 2 | 2023 | 116 | 0.390 |
Why?
| Heart Ventricles | 2 | 2013 | 712 | 0.390 |
Why?
| Disease Management | 1 | 2015 | 563 | 0.380 |
Why?
| Dementia | 3 | 2023 | 185 | 0.380 |
Why?
| Independent Living | 5 | 2018 | 84 | 0.380 |
Why?
| Hypothyroidism | 2 | 2009 | 65 | 0.380 |
Why?
| Health Surveys | 3 | 2014 | 446 | 0.380 |
Why?
| Kaplan-Meier Estimate | 14 | 2018 | 815 | 0.380 |
Why?
| Case-Control Studies | 11 | 2021 | 3022 | 0.370 |
Why?
| Insulin Resistance | 6 | 2013 | 1078 | 0.370 |
Why?
| Physical Fitness | 1 | 2012 | 179 | 0.370 |
Why?
| NAD | 2 | 2023 | 67 | 0.360 |
Why?
| Weight Loss | 1 | 2015 | 633 | 0.360 |
Why?
| Blood Coagulation Disorders | 2 | 2010 | 196 | 0.360 |
Why?
| Homeostasis | 5 | 2018 | 577 | 0.360 |
Why?
| Hospitalization | 3 | 2016 | 1765 | 0.360 |
Why?
| Mortality | 5 | 2020 | 290 | 0.360 |
Why?
| Hip Fractures | 3 | 2017 | 75 | 0.350 |
Why?
| Ischemia | 3 | 2011 | 363 | 0.350 |
Why?
| Zinc | 1 | 2012 | 256 | 0.350 |
Why?
| Dyslipidemias | 2 | 2013 | 154 | 0.350 |
Why?
| Polycystic Kidney Diseases | 2 | 2023 | 55 | 0.350 |
Why?
| Lovastatin | 1 | 2009 | 27 | 0.340 |
Why?
| Body Mass Index | 9 | 2017 | 1971 | 0.340 |
Why?
| Blood Coagulation | 3 | 2011 | 221 | 0.340 |
Why?
| gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.340 |
Why?
| Endocrine System Diseases | 1 | 2009 | 32 | 0.340 |
Why?
| Hospitals, Veterans | 2 | 2008 | 245 | 0.320 |
Why?
| Regional Blood Flow | 5 | 2017 | 414 | 0.320 |
Why?
| Uromodulin | 5 | 2022 | 21 | 0.320 |
Why?
| Fibrinolysis | 2 | 2011 | 160 | 0.320 |
Why?
| Bilirubin | 1 | 2009 | 91 | 0.320 |
Why?
| Severity of Illness Index | 12 | 2020 | 2578 | 0.310 |
Why?
| Sepsis | 1 | 2014 | 515 | 0.310 |
Why?
| Bone and Bones | 2 | 2012 | 283 | 0.310 |
Why?
| Diet | 2 | 2012 | 1072 | 0.310 |
Why?
| Patient Navigation | 2 | 2019 | 64 | 0.310 |
Why?
| Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.300 |
Why?
| Adolescent | 14 | 2023 | 17889 | 0.300 |
Why?
| Aging | 4 | 2021 | 1631 | 0.300 |
Why?
| Aorta | 3 | 2021 | 353 | 0.290 |
Why?
| Coronary Angiography | 3 | 2012 | 307 | 0.290 |
Why?
| Metabolomics | 4 | 2022 | 538 | 0.290 |
Why?
| Ultrasonography | 6 | 2013 | 641 | 0.290 |
Why?
| Brain | 2 | 2018 | 2370 | 0.290 |
Why?
| Aortic Aneurysm, Abdominal | 6 | 2011 | 114 | 0.280 |
Why?
| Pravastatin | 2 | 2023 | 28 | 0.280 |
Why?
| Angiotensin Receptor Antagonists | 2 | 2018 | 77 | 0.270 |
Why?
| Infant Mortality | 2 | 2018 | 91 | 0.270 |
Why?
| Lipocalin-2 | 3 | 2022 | 62 | 0.270 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 667 | 0.270 |
Why?
| Thrombosis | 1 | 2009 | 302 | 0.270 |
Why?
| Infant, Low Birth Weight | 2 | 2018 | 125 | 0.270 |
Why?
| Electric Countershock | 1 | 2007 | 104 | 0.270 |
Why?
| Professional Competence | 1 | 2006 | 86 | 0.270 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 3 | 2020 | 35 | 0.270 |
Why?
| Coronary Vessels | 3 | 2022 | 229 | 0.260 |
Why?
| Magnetic Resonance Imaging | 5 | 2021 | 3069 | 0.260 |
Why?
| Fasting | 4 | 2023 | 241 | 0.250 |
Why?
| Cross-Over Studies | 5 | 2018 | 434 | 0.250 |
Why?
| Anticholesteremic Agents | 1 | 2007 | 129 | 0.250 |
Why?
| Respiratory Muscles | 2 | 2023 | 32 | 0.250 |
Why?
| Deoxycholic Acid | 3 | 2022 | 15 | 0.250 |
Why?
| Quality of Life | 4 | 2020 | 2385 | 0.250 |
Why?
| Tryptophan | 2 | 2023 | 136 | 0.250 |
Why?
| Cognition Disorders | 3 | 2017 | 475 | 0.250 |
Why?
| Diabetes Mellitus, Type 1 | 7 | 2014 | 3254 | 0.250 |
Why?
| Blood Pressure Determination | 3 | 2020 | 122 | 0.240 |
Why?
| Pre-Eclampsia | 2 | 2018 | 165 | 0.240 |
Why?
| Survival Analysis | 6 | 2019 | 1219 | 0.240 |
Why?
| Nitric Oxide | 5 | 2023 | 832 | 0.240 |
Why?
| Mitochondria | 2 | 2021 | 750 | 0.230 |
Why?
| Linear Models | 6 | 2017 | 776 | 0.230 |
Why?
| Animals | 15 | 2023 | 32102 | 0.230 |
Why?
| Nephrotic Syndrome | 1 | 2003 | 25 | 0.230 |
Why?
| Nutritional Status | 2 | 2018 | 289 | 0.230 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 301 | 0.220 |
Why?
| Atrial Fibrillation | 2 | 2020 | 325 | 0.220 |
Why?
| Diet, Ketogenic | 1 | 2023 | 33 | 0.220 |
Why?
| Metabolome | 3 | 2022 | 287 | 0.220 |
Why?
| Confidence Intervals | 3 | 2012 | 309 | 0.220 |
Why?
| Colorado | 9 | 2021 | 4113 | 0.220 |
Why?
| Child | 9 | 2023 | 18488 | 0.220 |
Why?
| Recovery of Function | 3 | 2017 | 577 | 0.210 |
Why?
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 90 | 0.210 |
Why?
| Drug Therapy, Combination | 6 | 2020 | 962 | 0.210 |
Why?
| Guideline Adherence | 1 | 2006 | 497 | 0.210 |
Why?
| Compassion Fatigue | 1 | 2022 | 23 | 0.210 |
Why?
| Military Personnel | 1 | 2009 | 525 | 0.210 |
Why?
| Heart Failure | 8 | 2017 | 1963 | 0.210 |
Why?
| Physicians | 2 | 2022 | 776 | 0.210 |
Why?
| Antioxidants | 2 | 2018 | 533 | 0.200 |
Why?
| Troponin T | 3 | 2012 | 49 | 0.200 |
Why?
| Up-Regulation | 5 | 2019 | 820 | 0.200 |
Why?
| Diastole | 3 | 2013 | 134 | 0.200 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 225 | 0.200 |
Why?
| Exercise Tolerance | 1 | 2023 | 223 | 0.200 |
Why?
| Diabetes Mellitus | 4 | 2020 | 906 | 0.200 |
Why?
| Predictive Value of Tests | 11 | 2019 | 1805 | 0.190 |
Why?
| Breathing Exercises | 1 | 2021 | 19 | 0.190 |
Why?
| Niacinamide | 2 | 2020 | 65 | 0.190 |
Why?
| Inhalation | 1 | 2021 | 24 | 0.190 |
Why?
| Feasibility Studies | 2 | 2021 | 741 | 0.190 |
Why?
| Attitude of Health Personnel | 2 | 2018 | 990 | 0.190 |
Why?
| Propensity Score | 2 | 2019 | 225 | 0.190 |
Why?
| Stroke | 4 | 2017 | 1016 | 0.190 |
Why?
| Toxins, Biological | 1 | 2020 | 11 | 0.190 |
Why?
| Parathyroidectomy | 1 | 2020 | 7 | 0.190 |
Why?
| Culturally Competent Care | 1 | 2021 | 49 | 0.190 |
Why?
| Education | 2 | 2018 | 99 | 0.180 |
Why?
| Neutrophils | 1 | 2006 | 1172 | 0.180 |
Why?
| Carotid Intima-Media Thickness | 2 | 2018 | 65 | 0.180 |
Why?
| Osteoporotic Fractures | 2 | 2012 | 57 | 0.180 |
Why?
| Motor Activity | 2 | 2015 | 633 | 0.180 |
Why?
| Communication Barriers | 1 | 2021 | 90 | 0.180 |
Why?
| Intestinal Absorption | 1 | 2021 | 93 | 0.180 |
Why?
| Plaque, Atherosclerotic | 1 | 2021 | 43 | 0.180 |
Why?
| Propanolamines | 2 | 2011 | 94 | 0.180 |
Why?
| Netherlands | 8 | 2012 | 64 | 0.180 |
Why?
| Socioeconomic Factors | 3 | 2020 | 1086 | 0.180 |
Why?
| Cerebrovascular Circulation | 2 | 2023 | 202 | 0.180 |
Why?
| Sevelamer | 1 | 2020 | 9 | 0.180 |
Why?
| Allopurinol | 2 | 2018 | 55 | 0.180 |
Why?
| Placebos | 2 | 2012 | 198 | 0.180 |
Why?
| Focus Groups | 2 | 2020 | 393 | 0.180 |
Why?
| Hypokalemia | 1 | 2020 | 25 | 0.180 |
Why?
| Age Factors | 8 | 2018 | 2907 | 0.170 |
Why?
| Hyperkalemia | 1 | 2020 | 25 | 0.170 |
Why?
| Tunica Intima | 3 | 2010 | 78 | 0.170 |
Why?
| Organ Size | 2 | 2017 | 434 | 0.170 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 85 | 0.170 |
Why?
| Age Distribution | 2 | 2012 | 341 | 0.170 |
Why?
| Ambulatory Care Facilities | 1 | 2021 | 211 | 0.170 |
Why?
| Preoperative Period | 4 | 2014 | 103 | 0.170 |
Why?
| Immunosuppressive Agents | 1 | 2003 | 666 | 0.170 |
Why?
| Sex Distribution | 2 | 2012 | 337 | 0.170 |
Why?
| Pilot Projects | 3 | 2020 | 1377 | 0.170 |
Why?
| Acetates | 1 | 2020 | 96 | 0.170 |
Why?
| Patient Care Planning | 1 | 2020 | 142 | 0.170 |
Why?
| Mice | 8 | 2023 | 15052 | 0.160 |
Why?
| Lipoproteins, HDL | 1 | 2019 | 76 | 0.160 |
Why?
| Neuroimaging | 2 | 2018 | 247 | 0.160 |
Why?
| Infant, Newborn | 4 | 2018 | 5077 | 0.160 |
Why?
| Calcification, Physiologic | 1 | 2018 | 35 | 0.160 |
Why?
| Postoperative Complications | 6 | 2014 | 2161 | 0.160 |
Why?
| Health Services Accessibility | 3 | 2021 | 771 | 0.160 |
Why?
| Carnitine | 1 | 2018 | 61 | 0.160 |
Why?
| Reactive Oxygen Species | 4 | 2023 | 549 | 0.160 |
Why?
| Electrocardiography | 5 | 2020 | 560 | 0.160 |
Why?
| Potassium | 2 | 2020 | 128 | 0.150 |
Why?
| Fellowships and Scholarships | 2 | 2020 | 241 | 0.150 |
Why?
| Scandinavian and Nordic Countries | 2 | 2008 | 6 | 0.150 |
Why?
| Information Seeking Behavior | 1 | 2018 | 36 | 0.150 |
Why?
| Cholesterol, HDL | 4 | 2013 | 185 | 0.150 |
Why?
| Healthy Aging | 1 | 2018 | 17 | 0.150 |
Why?
| Pain | 2 | 2020 | 712 | 0.150 |
Why?
| Healthy Lifestyle | 1 | 2018 | 29 | 0.150 |
Why?
| Bone Diseases, Metabolic | 1 | 2018 | 53 | 0.150 |
Why?
| Peer Group | 1 | 2019 | 206 | 0.150 |
Why?
| Burnout, Professional | 1 | 2022 | 322 | 0.150 |
Why?
| Death | 1 | 2018 | 109 | 0.140 |
Why?
| Adaptive Immunity | 1 | 2018 | 157 | 0.140 |
Why?
| Hemodialysis Solutions | 1 | 2017 | 3 | 0.140 |
Why?
| Emergency Treatment | 1 | 2018 | 113 | 0.140 |
Why?
| Femoral Artery | 1 | 2018 | 167 | 0.140 |
Why?
| Preoperative Care | 2 | 2010 | 318 | 0.140 |
Why?
| Neuropsychological Tests | 2 | 2018 | 919 | 0.140 |
Why?
| Energy Metabolism | 1 | 2022 | 715 | 0.140 |
Why?
| Vasopressins | 1 | 2017 | 57 | 0.140 |
Why?
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 16 | 0.140 |
Why?
| Cholesterol, LDL | 3 | 2013 | 309 | 0.140 |
Why?
| Congenital Abnormalities | 1 | 2017 | 74 | 0.140 |
Why?
| Immunity, Humoral | 1 | 2017 | 112 | 0.140 |
Why?
| Mutation | 3 | 2022 | 3364 | 0.140 |
Why?
| Bile Acids and Salts | 1 | 2017 | 172 | 0.140 |
Why?
| Trehalose | 1 | 2016 | 29 | 0.140 |
Why?
| Pregnancy | 3 | 2018 | 5548 | 0.130 |
Why?
| Postoperative Period | 3 | 2011 | 292 | 0.130 |
Why?
| Liver Transplantation | 1 | 2003 | 830 | 0.130 |
Why?
| Living Donors | 1 | 2018 | 324 | 0.130 |
Why?
| Heart Rate | 2 | 2011 | 701 | 0.130 |
Why?
| Vascular Resistance | 2 | 2014 | 338 | 0.130 |
Why?
| Heart Arrest | 2 | 2016 | 289 | 0.130 |
Why?
| Heart Valve Diseases | 1 | 2017 | 116 | 0.130 |
Why?
| Lipogenesis | 1 | 2016 | 57 | 0.130 |
Why?
| Global Health | 2 | 2015 | 290 | 0.130 |
Why?
| Absorptiometry, Photon | 2 | 2017 | 221 | 0.130 |
Why?
| Risk Reduction Behavior | 2 | 2015 | 201 | 0.130 |
Why?
| Immunity, Cellular | 1 | 2017 | 262 | 0.130 |
Why?
| Stearoyl-CoA Desaturase | 1 | 2015 | 53 | 0.130 |
Why?
| Communicable Diseases | 1 | 2017 | 130 | 0.130 |
Why?
| Phosphatidylethanolamines | 1 | 2015 | 66 | 0.130 |
Why?
| Peptides | 1 | 2020 | 864 | 0.120 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2015 | 92 | 0.120 |
Why?
| Urinary Tract Infections | 1 | 2016 | 136 | 0.120 |
Why?
| Frail Elderly | 1 | 2016 | 105 | 0.120 |
Why?
| Analysis of Variance | 3 | 2012 | 1227 | 0.120 |
Why?
| Obstetric Labor, Premature | 1 | 2015 | 33 | 0.120 |
Why?
| Maternal Mortality | 1 | 2015 | 33 | 0.120 |
Why?
| Aorta, Abdominal | 2 | 2012 | 38 | 0.120 |
Why?
| Risk | 5 | 2019 | 819 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 4 | 2013 | 1870 | 0.120 |
Why?
| Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.120 |
Why?
| Metabolic Diseases | 2 | 2014 | 99 | 0.120 |
Why?
| Serine | 1 | 2015 | 125 | 0.120 |
Why?
| Italy | 5 | 2014 | 92 | 0.120 |
Why?
| Estrogen Replacement Therapy | 2 | 2014 | 116 | 0.120 |
Why?
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 2 | 0.120 |
Why?
| Acetylcholine | 3 | 2023 | 180 | 0.120 |
Why?
| Transcription Factor CHOP | 1 | 2014 | 28 | 0.120 |
Why?
| Renal Artery | 1 | 2014 | 26 | 0.120 |
Why?
| Transforming Growth Factor beta | 1 | 2017 | 446 | 0.120 |
Why?
| Inflammation Mediators | 1 | 2017 | 479 | 0.120 |
Why?
| Gastrointestinal Microbiome | 1 | 2020 | 503 | 0.120 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1265 | 0.120 |
Why?
| Infant, Small for Gestational Age | 1 | 2015 | 75 | 0.120 |
Why?
| Linoleic Acids, Conjugated | 1 | 2013 | 5 | 0.120 |
Why?
| Organophosphonates | 1 | 2014 | 91 | 0.120 |
Why?
| Sodium Chloride, Dietary | 1 | 2014 | 30 | 0.120 |
Why?
| Tocopherols | 1 | 2013 | 22 | 0.120 |
Why?
| Healthcare Disparities | 1 | 2019 | 485 | 0.110 |
Why?
| Endothelium | 1 | 2014 | 115 | 0.110 |
Why?
| Steroid Hydroxylases | 1 | 2013 | 19 | 0.110 |
Why?
| Sex Factors | 5 | 2018 | 1736 | 0.110 |
Why?
| NF-kappa B p50 Subunit | 1 | 2013 | 25 | 0.110 |
Why?
| Bufanolides | 1 | 2013 | 4 | 0.110 |
Why?
| Premature Birth | 1 | 2017 | 278 | 0.110 |
Why?
| Observational Studies as Topic | 1 | 2014 | 89 | 0.110 |
Why?
| Glucose | 1 | 2018 | 904 | 0.110 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 693 | 0.110 |
Why?
| Education, Medical, Graduate | 1 | 2017 | 376 | 0.110 |
Why?
| Statistics as Topic | 2 | 2017 | 299 | 0.110 |
Why?
| Cesarean Section | 1 | 2015 | 169 | 0.110 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 757 | 0.110 |
Why?
| Aortic Valve Stenosis | 2 | 2017 | 253 | 0.110 |
Why?
| Hypercapnia | 2 | 2023 | 50 | 0.110 |
Why?
| Adenine | 1 | 2014 | 221 | 0.110 |
Why?
| Intensive Care Units, Neonatal | 1 | 2015 | 179 | 0.100 |
Why?
| Ferric Compounds | 1 | 2012 | 40 | 0.100 |
Why?
| Institutionalization | 1 | 2012 | 12 | 0.100 |
Why?
| Glycation End Products, Advanced | 1 | 2012 | 57 | 0.100 |
Why?
| Endoplasmic Reticulum | 1 | 2014 | 235 | 0.100 |
Why?
| Causality | 2 | 2011 | 106 | 0.100 |
Why?
| Kynurenine | 2 | 2023 | 80 | 0.100 |
Why?
| Spinal Fractures | 1 | 2013 | 78 | 0.100 |
Why?
| Cytokines | 2 | 2018 | 1853 | 0.100 |
Why?
| Postoperative Care | 2 | 2010 | 222 | 0.100 |
Why?
| Aortic Aneurysm | 1 | 2012 | 50 | 0.100 |
Why?
| Tunica Media | 2 | 2010 | 35 | 0.100 |
Why?
| Echocardiography, Stress | 2 | 2010 | 20 | 0.100 |
Why?
| Sympathetic Nervous System | 2 | 2015 | 171 | 0.100 |
Why?
| Hospital Mortality | 2 | 2014 | 779 | 0.100 |
Why?
| Meta-Analysis as Topic | 1 | 2012 | 161 | 0.100 |
Why?
| Dietary Fiber | 1 | 2011 | 40 | 0.100 |
Why?
| Lung Neoplasms | 2 | 2014 | 2207 | 0.100 |
Why?
| International Classification of Diseases | 1 | 2012 | 118 | 0.100 |
Why?
| Hemostatic Disorders | 1 | 2011 | 1 | 0.100 |
Why?
| Drug Combinations | 1 | 2012 | 289 | 0.100 |
Why?
| Infant, Premature | 1 | 2015 | 477 | 0.090 |
Why?
| Qualitative Research | 3 | 2021 | 971 | 0.090 |
Why?
| Muscle Strength | 2 | 2023 | 275 | 0.090 |
Why?
| Cardiovascular System | 3 | 2020 | 124 | 0.090 |
Why?
| Heart Failure, Systolic | 1 | 2010 | 20 | 0.090 |
Why?
| Natriuretic Peptide, Brain | 1 | 2010 | 99 | 0.090 |
Why?
| Gout | 1 | 2010 | 37 | 0.090 |
Why?
| Length of Stay | 1 | 2015 | 958 | 0.090 |
Why?
| Carbazoles | 1 | 2010 | 80 | 0.090 |
Why?
| Mice, Inbred C57BL | 4 | 2023 | 4773 | 0.090 |
Why?
| Ticlopidine | 1 | 2010 | 55 | 0.090 |
Why?
| Thinness | 1 | 2010 | 87 | 0.090 |
Why?
| Alpha-Globulins | 2 | 2020 | 20 | 0.090 |
Why?
| beta 2-Microglobulin | 2 | 2020 | 45 | 0.090 |
Why?
| Aneurysm | 1 | 2009 | 29 | 0.090 |
Why?
| Proteinuria | 2 | 2014 | 78 | 0.090 |
Why?
| Delphi Technique | 2 | 2020 | 164 | 0.090 |
Why?
| Nisoldipine | 1 | 2009 | 6 | 0.080 |
Why?
| Enalapril | 1 | 2009 | 16 | 0.080 |
Why?
| Arterial Occlusive Diseases | 1 | 2009 | 73 | 0.080 |
Why?
| Texas | 1 | 2009 | 187 | 0.080 |
Why?
| Genetic Loci | 1 | 2010 | 264 | 0.080 |
Why?
| Cerebrovascular Disorders | 1 | 2009 | 82 | 0.080 |
Why?
| Radioisotope Renography | 1 | 2008 | 4 | 0.080 |
Why?
| Regression Analysis | 3 | 2019 | 959 | 0.080 |
Why?
| Tomography, Spiral Computed | 1 | 2008 | 24 | 0.080 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2008 | 33 | 0.080 |
Why?
| Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| Chelating Agents | 2 | 2020 | 71 | 0.080 |
Why?
| Infant | 3 | 2018 | 7979 | 0.080 |
Why?
| Population Groups | 1 | 2009 | 58 | 0.080 |
Why?
| Databases as Topic | 1 | 2008 | 64 | 0.080 |
Why?
| Diabetic Retinopathy | 1 | 2010 | 149 | 0.080 |
Why?
| Adenocarcinoma | 1 | 2014 | 799 | 0.080 |
Why?
| Perindopril | 1 | 2007 | 1 | 0.080 |
Why?
| Demography | 1 | 2009 | 261 | 0.080 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 790 | 0.080 |
Why?
| Aspirin | 1 | 2010 | 326 | 0.080 |
Why?
| Mice, Knockout | 3 | 2023 | 2604 | 0.070 |
Why?
| Endpoint Determination | 1 | 2008 | 69 | 0.070 |
Why?
| Osteogenesis | 2 | 2021 | 184 | 0.070 |
Why?
| Estradiol | 1 | 2010 | 452 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 324 | 0.070 |
Why?
| Testosterone | 1 | 2010 | 337 | 0.070 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2010 | 399 | 0.070 |
Why?
| Magnetic Resonance Angiography | 1 | 2008 | 209 | 0.070 |
Why?
| Peptide Fragments | 1 | 2010 | 675 | 0.070 |
Why?
| Triglycerides | 3 | 2013 | 473 | 0.070 |
Why?
| Forearm | 2 | 2017 | 114 | 0.070 |
Why?
| Protective Factors | 2 | 2016 | 87 | 0.060 |
Why?
| Contrast Media | 1 | 2008 | 362 | 0.060 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 963 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2009 | 395 | 0.060 |
Why?
| Immunity, Innate | 1 | 2011 | 731 | 0.060 |
Why?
| Outpatients | 1 | 2008 | 330 | 0.060 |
Why?
| Models, Biological | 2 | 2014 | 1646 | 0.060 |
Why?
| Phagocytosis | 1 | 2006 | 355 | 0.060 |
Why?
| Genotype | 2 | 2020 | 1786 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 795 | 0.060 |
Why?
| Respiratory Therapy | 1 | 2023 | 20 | 0.060 |
Why?
| Hemodialysis, Home | 1 | 2023 | 8 | 0.060 |
Why?
| Caregivers | 2 | 2020 | 713 | 0.060 |
Why?
| Nicotinamide Mononucleotide | 1 | 2023 | 11 | 0.060 |
Why?
| B7-1 Antigen | 1 | 2023 | 54 | 0.060 |
Why?
| Self-Help Groups | 1 | 2023 | 30 | 0.060 |
Why?
| Ultrasonography, Doppler | 1 | 2003 | 105 | 0.050 |
Why?
| Kidney Glomerulus | 1 | 2003 | 102 | 0.050 |
Why?
| Tryptophan Oxygenase | 1 | 2023 | 22 | 0.050 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 44 | 0.050 |
Why?
| Hand Strength | 1 | 2023 | 97 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1893 | 0.050 |
Why?
| Muscles | 1 | 2023 | 326 | 0.050 |
Why?
| Midazolam | 1 | 2022 | 43 | 0.050 |
Why?
| NADPH Oxidases | 2 | 2013 | 122 | 0.050 |
Why?
| Least-Squares Analysis | 2 | 2012 | 73 | 0.050 |
Why?
| Waist Circumference | 2 | 2012 | 122 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 211 | 0.050 |
Why?
| Endocannabinoids | 1 | 2022 | 37 | 0.050 |
Why?
| Blood Flow Velocity | 1 | 2023 | 324 | 0.050 |
Why?
| B7-H1 Antigen | 1 | 2023 | 139 | 0.050 |
Why?
| Vulnerable Populations | 1 | 2022 | 138 | 0.050 |
Why?
| Mice, Mutant Strains | 1 | 2022 | 271 | 0.050 |
Why?
| Activating Transcription Factor 4 | 1 | 2021 | 18 | 0.050 |
Why?
| Clinical Trials as Topic | 2 | 2019 | 941 | 0.050 |
Why?
| Phenotype | 2 | 2022 | 2829 | 0.050 |
Why?
| Social Isolation | 1 | 2021 | 54 | 0.050 |
Why?
| Hematinics | 1 | 2020 | 18 | 0.050 |
Why?
| Hepcidins | 1 | 2020 | 22 | 0.050 |
Why?
| Disease Models, Animal | 2 | 2022 | 3580 | 0.050 |
Why?
| Acute Disease | 2 | 2017 | 914 | 0.050 |
Why?
| Databases, Genetic | 1 | 2022 | 208 | 0.050 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1098 | 0.050 |
Why?
| Nephrologists | 1 | 2020 | 12 | 0.050 |
Why?
| Administrative Personnel | 1 | 2020 | 31 | 0.050 |
Why?
| HIV Infections | 1 | 2014 | 2473 | 0.040 |
Why?
| Social Stigma | 1 | 2021 | 88 | 0.040 |
Why?
| Calcium Compounds | 1 | 2020 | 4 | 0.040 |
Why?
| Asia | 1 | 2020 | 53 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2023 | 1127 | 0.040 |
Why?
| California | 2 | 2012 | 367 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 160 | 0.040 |
Why?
| Africa | 1 | 2020 | 96 | 0.040 |
Why?
| Serum Albumin | 1 | 2020 | 135 | 0.040 |
Why?
| Biopsy | 1 | 2003 | 1056 | 0.040 |
Why?
| Vitamin B Complex | 1 | 2020 | 37 | 0.040 |
Why?
| Drug Monitoring | 1 | 2021 | 184 | 0.040 |
Why?
| Stakeholder Participation | 1 | 2020 | 73 | 0.040 |
Why?
| Matched-Pair Analysis | 1 | 2019 | 34 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 414 | 0.040 |
Why?
| Drug Interactions | 1 | 2021 | 347 | 0.040 |
Why?
| Registries | 2 | 2021 | 1770 | 0.040 |
Why?
| Models, Animal | 1 | 2021 | 350 | 0.040 |
Why?
| Intracranial Aneurysm | 1 | 2020 | 91 | 0.040 |
Why?
| Health Literacy | 1 | 2021 | 166 | 0.040 |
Why?
| Urban Population | 1 | 2021 | 405 | 0.040 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2018 | 17 | 0.040 |
Why?
| Glucuronidase | 1 | 2018 | 42 | 0.040 |
Why?
| Ligands | 1 | 2020 | 569 | 0.040 |
Why?
| Renal Circulation | 1 | 2018 | 53 | 0.040 |
Why?
| Patients | 1 | 2020 | 164 | 0.040 |
Why?
| Chemokine CCL2 | 1 | 2018 | 105 | 0.040 |
Why?
| Self Concept | 1 | 2020 | 218 | 0.040 |
Why?
| Career Choice | 1 | 2020 | 183 | 0.040 |
Why?
| Aftercare | 1 | 2020 | 187 | 0.040 |
Why?
| Symptom Flare Up | 1 | 2018 | 40 | 0.040 |
Why?
| Pyridinium Compounds | 1 | 2018 | 13 | 0.040 |
Why?
| Sodium Chloride Symporter Inhibitors | 1 | 2018 | 9 | 0.040 |
Why?
| Publications | 1 | 2018 | 37 | 0.040 |
Why?
| Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.040 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 145 | 0.040 |
Why?
| Fibrosis | 1 | 2020 | 457 | 0.040 |
Why?
| Fathers | 1 | 2018 | 45 | 0.040 |
Why?
| Consensus | 1 | 2020 | 532 | 0.040 |
Why?
| Activities of Daily Living | 1 | 2020 | 352 | 0.040 |
Why?
| Calcium Channel Blockers | 1 | 2018 | 115 | 0.040 |
Why?
| NF-kappa B | 2 | 2012 | 639 | 0.040 |
Why?
| Intelligence Tests | 1 | 2017 | 59 | 0.040 |
Why?
| Mitral Valve Stenosis | 1 | 2017 | 19 | 0.040 |
Why?
| Cholesterol | 1 | 2019 | 369 | 0.040 |
Why?
| Healthy Volunteers | 1 | 2018 | 192 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 414 | 0.040 |
Why?
| Interleukin-18 | 1 | 2018 | 222 | 0.040 |
Why?
| Safety-net Providers | 1 | 2018 | 96 | 0.040 |
Why?
| Femur Neck | 1 | 2017 | 60 | 0.040 |
Why?
| Quality of Health Care | 1 | 2021 | 576 | 0.030 |
Why?
| Diuretics | 1 | 2016 | 67 | 0.030 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2018 | 154 | 0.030 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 1718 | 0.030 |
Why?
| Methemoglobin | 1 | 2015 | 19 | 0.030 |
Why?
| Hip Joint | 1 | 2017 | 131 | 0.030 |
Why?
| White Matter | 1 | 2017 | 103 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 347 | 0.030 |
Why?
| Interviews as Topic | 1 | 2018 | 596 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2022 | 844 | 0.030 |
Why?
| Program Development | 1 | 2018 | 350 | 0.030 |
Why?
| Anthropometry | 1 | 2016 | 181 | 0.030 |
Why?
| Research | 1 | 2018 | 396 | 0.030 |
Why?
| Elasticity | 1 | 2015 | 194 | 0.030 |
Why?
| Urinalysis | 1 | 2015 | 62 | 0.030 |
Why?
| Patient Satisfaction | 1 | 2019 | 585 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2016 | 167 | 0.030 |
Why?
| Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| Renal Elimination | 1 | 2014 | 6 | 0.030 |
Why?
| Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| Age of Onset | 1 | 2016 | 450 | 0.030 |
Why?
| Research Design | 2 | 2011 | 946 | 0.030 |
Why?
| Actigraphy | 1 | 2015 | 73 | 0.030 |
Why?
| Vasodilator Agents | 1 | 2017 | 308 | 0.030 |
Why?
| Needs Assessment | 1 | 2017 | 318 | 0.030 |
Why?
| Societies, Medical | 1 | 2018 | 684 | 0.030 |
Why?
| Ketocholesterols | 1 | 2014 | 8 | 0.030 |
Why?
| France | 1 | 2014 | 34 | 0.030 |
Why?
| Immunotherapy | 1 | 2018 | 479 | 0.030 |
Why?
| Prostaglandins | 1 | 2014 | 78 | 0.030 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 39 | 0.030 |
Why?
| Health Personnel | 1 | 2020 | 581 | 0.030 |
Why?
| Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| Dilatation, Pathologic | 1 | 2014 | 54 | 0.030 |
Why?
| Azetidines | 1 | 2014 | 31 | 0.030 |
Why?
| Osteoporosis | 1 | 2017 | 227 | 0.030 |
Why?
| Apolipoproteins E | 1 | 2014 | 81 | 0.030 |
Why?
| F2-Isoprostanes | 1 | 2013 | 14 | 0.030 |
Why?
| Erythropoiesis | 1 | 2013 | 33 | 0.030 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2013 | 13 | 0.030 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 16 | 0.030 |
Why?
| Early Medical Intervention | 1 | 2014 | 51 | 0.030 |
Why?
| Acute Coronary Syndrome | 1 | 2017 | 254 | 0.030 |
Why?
| Signal Transduction | 2 | 2018 | 4541 | 0.030 |
Why?
| Aortic Valve | 1 | 2017 | 342 | 0.030 |
Why?
| Executive Function | 1 | 2018 | 373 | 0.030 |
Why?
| Cells, Cultured | 1 | 2021 | 3914 | 0.030 |
Why?
| Pulse | 1 | 2013 | 26 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2022 | 2125 | 0.030 |
Why?
| Program Evaluation | 1 | 2018 | 836 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 1970 | 0.030 |
Why?
| Tenofovir | 1 | 2014 | 205 | 0.030 |
Why?
| Blood Glucose | 2 | 2012 | 1824 | 0.030 |
Why?
| Immunoblotting | 1 | 2013 | 281 | 0.030 |
Why?
| Insulin | 2 | 2013 | 2082 | 0.030 |
Why?
| Albumins | 1 | 2013 | 91 | 0.030 |
Why?
| Cell Line | 1 | 2018 | 2651 | 0.030 |
Why?
| Random Allocation | 1 | 2013 | 337 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2013 | 398 | 0.030 |
Why?
| Epithelial Cells | 1 | 2018 | 961 | 0.030 |
Why?
| Biological Availability | 1 | 2012 | 119 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2014 | 724 | 0.030 |
Why?
| Xanthine Oxidase | 1 | 2012 | 72 | 0.030 |
Why?
| Germany | 1 | 2012 | 86 | 0.030 |
Why?
| Aspartate Aminotransferases | 1 | 2012 | 87 | 0.030 |
Why?
| Ventricular Remodeling | 1 | 2014 | 225 | 0.030 |
Why?
| Microcirculation | 1 | 2012 | 138 | 0.030 |
Why?
| Stress, Psychological | 1 | 2020 | 974 | 0.030 |
Why?
| Mothers | 1 | 2018 | 666 | 0.030 |
Why?
| In Vitro Techniques | 1 | 2013 | 1044 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2012 | 129 | 0.020 |
Why?
| Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| Metoprolol | 1 | 2011 | 37 | 0.020 |
Why?
| Aortic Diseases | 1 | 2012 | 95 | 0.020 |
Why?
| Nitroglycerin | 1 | 2010 | 22 | 0.020 |
Why?
| Stroke Volume | 1 | 2013 | 509 | 0.020 |
Why?
| Salicylates | 1 | 2010 | 30 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2012 | 343 | 0.020 |
Why?
| Arteries | 1 | 2012 | 250 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| Lipids | 1 | 2014 | 588 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2011 | 374 | 0.020 |
Why?
| Sunlight | 1 | 2010 | 57 | 0.020 |
Why?
| Area Under Curve | 1 | 2010 | 278 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 2012 | 332 | 0.020 |
Why?
| Life Style | 1 | 2012 | 429 | 0.020 |
Why?
| Echocardiography | 1 | 2012 | 558 | 0.020 |
Why?
| Elective Surgical Procedures | 1 | 2010 | 154 | 0.020 |
Why?
| Thyroid Function Tests | 1 | 2009 | 11 | 0.020 |
Why?
| ROC Curve | 1 | 2010 | 451 | 0.020 |
Why?
| Cystatins | 1 | 2008 | 6 | 0.020 |
Why?
| Myocardial Ischemia | 1 | 2010 | 237 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 2262 | 0.020 |
Why?
| Cardiovascular Surgical Procedures | 1 | 2008 | 30 | 0.020 |
Why?
| Dobutamine | 1 | 2007 | 33 | 0.020 |
Why?
| Exercise | 1 | 2018 | 1609 | 0.020 |
Why?
| Morbidity | 1 | 2008 | 278 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 1829 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2013 | 1048 | 0.020 |
Why?
| Angioplasty, Balloon, Coronary | 1 | 2008 | 146 | 0.020 |
Why?
| Perioperative Care | 1 | 2008 | 126 | 0.020 |
Why?
| Electronic Health Records | 1 | 2013 | 805 | 0.020 |
Why?
| Hemodynamics | 1 | 2011 | 968 | 0.020 |
Why?
| Rats | 1 | 2013 | 5034 | 0.020 |
Why?
| Ventricular Function, Left | 1 | 2007 | 467 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2012 | 1008 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2016 | 4665 | 0.010 |
Why?
| Genome-Wide Association Study | 1 | 2010 | 1217 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|